Enanta Pharmaceuticals (ENTA) EBIAT (2016 - 2025)
Historic EBIAT for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to -$11.9 million.
- Enanta Pharmaceuticals' EBIAT rose 4644.24% to -$11.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$71.5 million, marking a year-over-year increase of 3182.28%. This contributed to the annual value of -$81.9 million for FY2025, which is 2943.34% up from last year.
- Enanta Pharmaceuticals' EBIAT amounted to -$11.9 million in Q4 2025, which was up 4644.24% from -$18.7 million recorded in Q3 2025.
- In the past 5 years, Enanta Pharmaceuticals' EBIAT ranged from a high of -$11.9 million in Q4 2025 and a low of -$39.1 million during Q2 2023
- Moreover, its 5-year median value for EBIAT was -$27.2 million (2022), whereas its average is -$26.8 million.
- Its EBIAT has fluctuated over the past 5 years, first tumbled by 26711.07% in 2021, then soared by 4644.24% in 2025.
- Over the past 5 years, Enanta Pharmaceuticals' EBIAT (Quarter) stood at -$30.1 million in 2021, then increased by 3.75% to -$29.0 million in 2022, then fell by 15.25% to -$33.4 million in 2023, then surged by 33.28% to -$22.3 million in 2024, then soared by 46.44% to -$11.9 million in 2025.
- Its EBIAT was -$11.9 million in Q4 2025, compared to -$18.7 million in Q3 2025 and -$18.3 million in Q2 2025.